RE-BVS – Piemonte Repository

Sfoglia per RIVISTA
CANCER
Collezione AOU Novara

Items : 6

Upfront intensive treatment analysis of the Italian Cohort Study on FLT3-mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real-life setting. in Cancer / Cancer. 2025 Apr 1;131(7):e35824. doi: 10.1002/cncr.35824.

2025
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
AOU Novara

Marconi G; Petracci E; Valli I; Volpi R; Zamagni F; Mattei A; Ottaviani E; Bochicchio MT; Bocchia M; Todisco E; Cilloni D; Rigolin GM; Giannini MB; Bernardi M; Romani C; Fracchiolla N; Olivieri A; Albano F; Lunghi M; Cambò B; Candoni A; Scappini B; Chiusolo P; Audisio E; Martelli MP; Martinelli G; Mulè A; Papayannidis C; Azzali I; et alii...

Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia. in Cancer / Cancer. 2024 Jan;130(2):287-299. doi: 10.1002/cncr.35021. Epub 2023 Oct 6.

2024
AOU Città della Salute di Torino
AOU Novara

Cella D; Vignetti M; Cortes J; Rosti G; Dinner S; Altman JK; Abruzzese E; Fava C; Iurlo A; Giai V; Luciano L; Tiribelli M; Breccia M; Miggiano MC; Patriarca A; Capodanno I; Bonifacio M; Caocci G; Castagnetti F; Kota V; Yanez B; Cottone F; Efficace F;

Determinants of frontline tyrosine kinase inhibitor choice for patients with chronic-phase chronic myeloid leukemia: A study from the Registro Italiano LMC and Campus CML. in Cancer / Cancer. 2023 Sep 1;129(17):2637-2644. doi: 10.1002/cncr.34923. Epub 2023 Jun 24.

2023
AO Cuneo
AOU Novara

Pizzuti M; Crugnola M; Malato A; Fava C; Bocchia M; Vincelli I; Luzi D; Rapezzi D; Abruzzese E; Stagno F; Murgano P; Sancetta R; Leporace AP; Scortechini AR; Crisà E; Binotto G; Maggi A; Loglisci G; Mulas O; Bonifacio M; Sorà F; Annunziata M; Russo S; Crescenzi SL; Attolico I; Bucelli C; Cavazzini F; Miggiano MC; Capodanno I; et alii...

AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia. in Cancer / Cancer. 2023 Apr 1;129(7):992-1004. doi: 10.1002/cncr.34608. Epub 2023 Jan 24.

2023
AO Cuneo
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara

Martinelli G; Rossi G; Volpi R; Sciumè M; Tarella C; Marconi G; Federico V; Romano A; Cardinali V; Gigli F; Roncoroni E; Ferrara F; Maurillo L; Nanni J; Rivellini F; Cascavilla N; Fianchi L; Cilloni D; Lanza F; Abruzzese E; Martini V; Lunghi M; Molteni A; Gottardi M; Salutari P; Cairoli R; Borlenghi E; Basilico CM; Manfra I; et alii...

Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice. in Cancer / Cancer. 2021 Jun 15;127(12):2015-2024. doi: 10.1002/cncr.33472. Epub 2021 Mar 19.

2021
AOU Città della Salute di Torino
AOU Novara

Santini V; Angelucci E; Musto P; Capalbo SF; Abbadessa A; Castelli A; Catarini M; Alesiani F; Centurioni R; Crugnola M; Oliva EN; Bigazzi C; Zambello R; Fanin R; Freilone R; Cametti G; Di Tucci AA; Danise P; Cilloni D; Selleri C; Finelli C; Poloni A; Balleari E; Ferrero D; Allione B; Salvi F; Ceccarelli M; Guolo F; Miglino M; et alii...

Beta-2-microglobulin is an independent predictor of progression in asymptomatic multiple myeloma. in Cancer / Cancer. 2010 May 1;116(9):2188-200. doi: 10.1002/cncr.24959.

2010
AOU Novara

Rossi D; Fangazio M; De Paoli L; Puma A; Riccomagno P; Pinto V; Zigrossi P; Ramponi A; Monga G; Gaidano G;